Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.

Phillip D MonkJody L BrookesVictoria J TearToby N BattenMarcin MankowskiTatjana Adzic-VukicevicMichael G CrooksDavinder P S DosanjhMonica KraftChristopher E BrightlingFelicity J GabbayStephen T HolgateRatko DjukanovicTom M A Wilkinson

Published in: ERJ open research (2023)

Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.

Keyphrases

phase iii
sars cov
clinical trial
open label
randomized controlled trial
community acquired pneumonia